COMPARISON OF REAL-WORLD LATER-LINE TREATMENT OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH (MSI-H) VERSUS MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES (US)

被引：0
|
作者：
Dixon, M. [1 ]
Gu, J. [1 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO53
引用
收藏
页码：S313 / S314
页数：2
相关论文
共 50 条
  • [41] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
  • [42] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [43] Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Bhave, Manali Ajay
    Ntalla, Ioanna
    Lai, Catherine
    Sjekloca, Nikoleta
    Stwalley, Brian
    Stokes, Michael
    Taylor, Aliki
    Nanda, Rita
    BREAST CANCER RESEARCH AND TREATMENT, 2024, : 203 - 214
  • [44] Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
    Agg, Himani
    Han, Yimei
    Cui, Zhanglin Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Yoshino, T.
    Andre, T.
    Kim, T. W.
    Yong, W. P.
    Shiu, K-K.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez Fernandez, M. E.
    Le, D. T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
  • [47] Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in community oncology practices in the United States (US).
    Ivanova, Jasmina I.
    Saverno, Kimberly
    Sung, Jennifer
    Duh, Mei Sheng
    Zhao, Chen
    Cai, Xiaopeng
    Vekeman, Francis
    Peevyhouse, Aaron
    Dhawan, Ravinder
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023.
    Pothuri, Bhavana
    Thaker, Premal H.
    Tymejczyk, Olga
    Reiss, Samantha
    Nitti, Giovanni
    Cain, Theresa
    Hada, Manila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A propensity score-matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: Real-world data
    He, Lina
    Cheng, Xiaojiao
    Cheng, Xin
    Zhou, Cong
    Li, Qingli
    Tu, Shuiping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
    Meltzer, S.
    Berg, J. P.
    Hamre, H. M.
    Kersten, C.
    Hofsli, E.
    Guren, M. G.
    Sorbye, H.
    Flatmark, K.
    Ree, A. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S449 - S449
12345